Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
621-640 of 2,120 trials

Familial Mediterranean Fever: On-Demand Anakinra Treatment

We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.

Familial Mediterranean Fever>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious DiseasesInternal MedicineRheumatology

Penile Cancer: Carboplatin, Paclitaxel, and Pembrolizumab Study

We are studying a combination of chemotherapy and immunotherapy for patients with locoregionally advanced penile cancer. The goal is to see if this treatment can effectively shrink tumors before surgery and to assess its safety.

Locoregionally Advanced Penile Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Gastric Cancer: EXL01 with Nivolumab and FOLFOX

We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.

Metastatic Gastric Adenocarcinoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Pain Relief for Kids: Fentanyl vs. Ketamine vs. Morphine

We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.

Limb InjuriesUrgency>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Neurodegenerative Disease: Continued Access to Latozinemab

We are offering ongoing access to the medication latozinemab for individuals with neurodegenerative diseases who have participated in earlier studies. The trial will monitor safety and any clinical benefits from continued treatment.

Neurodegenerative DisordersConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

LSTA1 for Newly Diagnosed Glioblastoma Multiforme

We are studying whether adding LSTA1 to standard treatment (temozolomide) improves survival for patients with newly diagnosed GBM compared to a placebo. The trial also looks at quality of life and other important health measures.

Glioblastoma Multiforme>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Prostate Cancer: Intermittent vs. Continuous Hormone Therapy

We are studying whether intermittent hormone therapy can maintain effectiveness and improve daily life for men with advanced prostate cancer. This trial compares it to continuous hormone therapy to see which is better for patients.

Hormone-sensitive Metastatic Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Recurrent Gynecological Cancers: IMGN151 Study

We are testing a new drug, IMGN151, in women with recurrent gynecological cancers to assess its safety and determine the best dose. This study aims to understand how well the drug works and its effects on patients.

Recurrent Gynecological Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Chronic Kidney Disease: Teriparatide for Bone Health

We are studying whether teriparatide can improve bone metabolism in patients with chronic kidney disease and adynamic bone disorder. This trial compares the effects of treatment to no treatment at all.

Adynamic Bone Disorder>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyOrthopedics and Traumatology

Metastatic Prostate Cancer: ProBio Study

We are investigating if treatment choices based on biomarker signatures can improve survival and quality of life for patients with metastatic prostate cancer. This study compares these personalized approaches to standard care.

Metastatic Prostate CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Staphylococcus Aureus Bacteraemia: Bensylpenicillin vs. Cloxacillin

We are comparing two antibiotics to see which one works better for patients with a specific bacterial infection. The study looks at treatment outcomes, relapse rates, and side effects.

Staphylococcus aureus Bacteraemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Chronic Hepatitis B: Long-Term Study on Treatment Response

We are investigating how well previous participants of a hepatitis B treatment maintain their health over time. This study focuses on those who have stopped certain therapies and aims to understand their long-term outcomes.

Chronic Hepatitis BEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInfectious Diseases

Heart Attack Recovery: Ziltivekimab Study

We are investigating how ziltivekimab may improve heart health in people who have had a heart attack compared to a placebo. This study aims to see if it can reduce serious heart-related issues.

Heart Attack>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Rectal Adenocarcinoma: Contact X-Ray Brachytherapy Study

We are studying whether adding contact X-ray brachytherapy to standard treatment can help preserve the rectum and improve survival in patients with intermediate substage rectal adenocarcinoma. We will also assess its impact on quality of life and side effects.

Rectal Adenocarcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Liver Cancer: Fecal Microbiota Transfer Study

We are investigating whether fecal microbiota transfer can help liver cancer patients who are resistant to standard treatments. The study aims to improve immune response and overall survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHepatologyInternal MedicineOncology

Lung Cancer: Durvalumab and Domvanalimab Study

We are studying a combination of two medications for patients with stage III unresectable non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this combination improves survival and disease control compared to standard treatment.

Lung Cancer6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Follicular Lymphoma: Epcoritamab with Rituximab and Lenalidomide

We are studying a new treatment combination for adults with previously untreated follicular lymphoma. The goal is to see if it works better and has fewer side effects than standard chemotherapy.

Follicular LymphomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Oocyte Donation: Corifollitropin alfa vs. Daily rFSH

We are studying whether Corifollitropin alfa can help increase the number of eggs collected from oocyte donors compared to standard daily treatments. This trial involves women using hormone suppression to improve egg quality.

Female Infertility1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and Obstetrics

Stroke Treatment: Intra-Arterial Thrombolysis Study

We are studying whether adding a specific clot-dissolving treatment helps improve recovery in patients with acute strokes who have already had successful blood flow restoration. This trial will also evaluate safety and costs associated with this treatment.

Ischemic Stroke1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology